Dual EGFR-TGFβ Blockade Achieves 54% Response Rate in Hard-to-Treat Head and Neck Cancer
Ficerafusp alfa plus pembrolizumab shows striking results in HPV-negative head and neck cancer, a notoriously difficult-to-treat population.
Summary
A new combination therapy pairing ficerafusp alfa — a bispecific antibody that blocks both EGFR and TGF-β — with the checkpoint inhibitor pembrolizumab showed strong early results in patients with recurrent or metastatic head and neck squamous cell carcinoma. In the 28 HPV-negative patients, who typically respond poorly to immunotherapy, the objective response rate was 54%, including 21% complete responses. Median overall survival reached 21.3 months — a meaningful improvement over historical benchmarks. Side effects were manageable, with no unexpected safety signals. These two-year results from a Phase I/Ib trial support advancing this combination into larger studies, and may represent a significant shift in how HPV-negative head and neck cancer is treated in the first-line setting.
Detailed Summary
Head and neck squamous cell carcinoma that has recurred or spread to distant sites carries a grim prognosis, especially in patients whose tumors are not driven by HPV. In this population, high levels of EGFR and TGF-β actively suppress immune cell infiltration into tumors, blunting the effectiveness of standard immunotherapy. A novel bispecific antibody, ficerafusp alfa, was designed to simultaneously neutralize both pathways, potentially restoring immune access to the tumor microenvironment.
This expansion cohort from a Phase I/Ib trial enrolled 42 patients with PD-L1-positive recurrent or metastatic HNSCC between February 2022 and April 2023. Patients received ficerafusp alfa 1,500 mg weekly plus pembrolizumab 200 mg every three weeks as first-line therapy. After a median follow-up of 26.3 months, efficacy was assessed in 39 patients with at least one post-baseline scan.
The results in HPV-negative patients were particularly striking. Of 28 evaluable patients, 54% achieved an objective response, including 21% complete responses — a high bar in this disease. Median duration of response was 21.7 months, median progression-free survival was 9.9 months, and median overall survival reached 21.3 months. By contrast, HPV-positive patients had a lower 27% response rate, possibly reflecting a different immunological baseline. Safety was acceptable: 45% of patients experienced grade 3 treatment-related adverse events, predominantly anemia and acneiform dermatitis, with only one grade 4 event.
These findings are clinically meaningful because HPV-negative HNSCC has historically responded poorly to checkpoint inhibitor monotherapy. The dual blockade strategy appears to overcome key mechanisms of immune evasion specific to this subtype.
Caveats include the single-arm, non-randomized design and modest sample size, which limit definitive conclusions. The summary is based on abstract data only, and full trial data have not been independently reviewed here.
Key Findings
- 54% objective response rate in HPV-negative R/M HNSCC patients, including 21% complete responses.
- Median overall survival of 21.3 months in HPV-negative subgroup — notably high for this poor-prognosis population.
- Median duration of response reached 21.7 months, suggesting durable disease control in responders.
- Grade ≥3 adverse events in 45% of patients, mostly anemia and acneiform dermatitis — no unexpected toxicities.
- HPV-positive patients had lower 27% ORR, suggesting the dual EGFR-TGFβ blockade targets HPV-negative biology specifically.
Methodology
This is an expansion cohort of a first-in-human Phase I/Ib trial (NCT04429542) enrolling 42 PD-L1-positive R/M HNSCC patients treated with ficerafusp alfa plus pembrolizumab as first-line therapy. Primary endpoint was safety; secondary endpoints included ORR, PFS, DOR, and OS. Median follow-up was 26.3 months, with efficacy assessed in 39 patients with at least one post-baseline scan.
Study Limitations
The study is a non-randomized, single-arm expansion cohort with only 42 patients, precluding direct comparison to standard-of-care pembrolizumab monotherapy. Small subgroup sizes, particularly 11 HPV-positive patients, limit subgroup conclusions. This summary is based on the abstract only, as the full manuscript was not available for review.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.